Martin J. Hughes
Nessuna posizione attualmente
Profilo
Martin J.
Hughes worked as a Director of Quality, Regulatory & Clinical Affairs at Myconostica Ltd.
and as a Senior Scientist at Microscience Ltd.
He also worked as a Principal at F2G Ltd.
from 2002 to 2009.
Hughes earned a doctorate degree from The University of Nottingham in 1991.
Precedenti posizioni note di Martin J. Hughes
| Società | Posizione | Fine |
|---|---|---|
Microscience Ltd.
 Microscience Ltd. Pharmaceuticals: MajorHealth Technology Microscience is an emerging vaccine company which is primarily involved in the discovery and development of innovative, rationally designed vaccines and immunotherapeutics for the prevention and treatment of disease in areas that the Company believes to represent a significant opportunity for new vaccines | Corporate Officer/Principal | - |
F2G Ltd.
 F2G Ltd. Pharmaceuticals: MajorHealth Technology F2G Ltd. provides novel drugs for the treatment of life-threatening systemic fungal diseases. It primarily focuses on developing an F3 series of anti mould compound, which is an antifungal agent that acts through a mechanism different from marketed drugs. The company was founded in 1998 and is headquartered in Manchester, the United Kingdom. | Corporate Officer/Principal | - |
Myconostica Ltd.
 Myconostica Ltd. Electronic Equipment/InstrumentsElectronic Technology Myconostica Ltd. developed molecular diagnostic fungal testing kits. The company was founded in February 2006 and is headquartered in Cambridge, the United Kingdom. | Chief Tech/Sci/R&D Officer | - |
Formazione di Martin J. Hughes
| The University of Nottingham | Doctorate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Aziende private | 3 |
|---|---|
Microscience Ltd.
Microscience Ltd. Pharmaceuticals: MajorHealth Technology Microscience is an emerging vaccine company which is primarily involved in the discovery and development of innovative, rationally designed vaccines and immunotherapeutics for the prevention and treatment of disease in areas that the Company believes to represent a significant opportunity for new vaccines | Health Technology |
Myconostica Ltd.
Myconostica Ltd. Electronic Equipment/InstrumentsElectronic Technology Myconostica Ltd. developed molecular diagnostic fungal testing kits. The company was founded in February 2006 and is headquartered in Cambridge, the United Kingdom. | Electronic Technology |
F2G Ltd.
F2G Ltd. Pharmaceuticals: MajorHealth Technology F2G Ltd. provides novel drugs for the treatment of life-threatening systemic fungal diseases. It primarily focuses on developing an F3 series of anti mould compound, which is an antifungal agent that acts through a mechanism different from marketed drugs. The company was founded in 1998 and is headquartered in Manchester, the United Kingdom. | Health Technology |
- Borsa valori
- Insiders
- Martin J. Hughes
